Upgrade to SI Premium - Free Trial

Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

June 30, 2026 11:00 AM
Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented: "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments